A student-run resource for reliable reports on the latest law and technology news

Written Description Problems of the Monoclonal Antibody Patents after Centocor v. Abbott 

Written By: Hyeongsu Park - Edited By: Kendra Albert

The market for therapeutic antibodies is projected to reach hundreds of billion dollars within the next several years. In Centocor v. Abbott, the Court of Appeals for the Federal Circuit (“Federal Circuit”) held that a patentee cannot claim an antibody unless the specification describes it, even if he/she fully characterizes the antigen, and the court vacated a $1.67 billion jury verdict, the largest patent infringement award in U.S. history.

Read More...

Posted On Mar - 13 - 2014 Comments Off READ FULL POST
  • RSS
  • Facebook
  • Twitter
  • GooglePlay
Photo By: archie4oz - CC BY 2.0

Silk Road 2.0 Takedo

  [caption id="attachment_4363" align="alignleft" width="150"] Photo By: archie4oz - CC BY ...

Unknown

Federal Circuit Flas

By Ken Winterbottom Motion to Dismiss in Hulu Patent Infringement Suit ...

GOOGLE_APTHDVR_1268416f

Spain Passes a “Go

By Michael Shammas — Edited by Yixuan Long Amendments to the ...

radio-wireless-tower-clip-art_resized

Federal Circuit Tigh

By Kathleen McGuinness – Edited by Sabreena Khalid Azure Networks, LLC ...

Unknown

Flash Digest: News i

By Viviana Ruiz Russia’s Intellectual Property Court affirms denial of Ford's ...